Daily Pill Doubles Survival Time for Pancreatic Cancer

A new pill called daraxonrasib has doubled survival time for advanced pancreatic cancer patients in a groundbreaking 500-person trial.

Oncologists are calling it a grand slam after four decades of failed attempts to crack the disease.